The stock has a 36-month beta value of 0.74. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PLX is 68.06M, and at present, short sellers hold a 4.67% of that float. On December 06, 2024, the average trading volume of PLX was 259.19K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PLX) stock’s latest price update
Protalix BioTherapeutics Inc (AMEX: PLX)’s stock price has soared by 2.45 in relation to previous closing price of 1.63. Nevertheless, the company has seen a loss of -2.91% in its stock price over the last five trading days. seekingalpha.com reported 2024-11-14 that Protalix BioTherapeutics, Inc. (NYSE:PLX ) Q3 2024 Results Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Mike Moyer – Investor Relations, LifeSci Advisors Dror Bashan – President and Chief Executive Officer Eyal Rubin – Senior Vice President and Chief Financial Officer Conference Call Participants John Vandermosten – Zacks Investment Research Daniel Smith – H.C. Wainwright & Co., LLC Robert Sassoon – Water Tower Research Operator Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Third Quarter 2024 Financial and Business Results Conference Call.
PLX’s Market Performance
Protalix BioTherapeutics Inc (PLX) has seen a -2.91% fall in stock performance for the week, with a 36.89% gain in the past month and a 65.35% surge in the past quarter. The volatility ratio for the week is 3.93%, and the volatility levels for the past 30 days are at 6.97% for PLX. The simple moving average for the past 20 days is 7.40% for PLX’s stock, with a 39.76% simple moving average for the past 200 days.
Analysts’ Opinion of PLX
Many brokerage firms have already submitted their reports for PLX stocks, with H.C. Wainwright repeating the rating for PLX by listing it as a “Buy.” The predicted price for PLX in the upcoming period, according to H.C. Wainwright is $11 based on the research report published on June 08, 2020 of the previous year 2020.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see PLX reach a price target of $5, previously predicting the price at $4. The rating they have provided for PLX stocks is “Buy” according to the report published on April 17th, 2017.
Rodman & Renshaw gave a rating of “Buy” to PLX, setting the target price at $3.50 in the report published on April 04th of the previous year.
PLX Trading at 30.53% from the 50-Day Moving Average
After a stumble in the market that brought PLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.11% of loss for the given period.
Volatility was left at 6.97%, however, over the last 30 days, the volatility rate increased by 3.93%, as shares surge +44.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +57.01% upper at present.
During the last 5 trading sessions, PLX fell by -2.33%, which changed the moving average for the period of 200-days by +17.48% in comparison to the 20-day moving average, which settled at $1.5555. In addition, Protalix BioTherapeutics Inc saw -6.18% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PLX
Current profitability levels for the company are sitting at:
- -0.2 for the present operating margin
- 0.36 for the gross margin
The net margin for Protalix BioTherapeutics Inc stands at -0.21. The total capital return value is set at -0.24. Equity return is now at value -27.18, with -12.88 for asset returns.
Currently, EBITDA for the company is 11.65 million with net debt to EBITDA at 3.36. When we switch over and look at the enterprise to sales, we see a ratio of 2.22. The receivables turnover for the company is 20.81for trailing twelve months and the total asset turnover is 0.74. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.98.
Conclusion
To sum up, Protalix BioTherapeutics Inc (PLX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
